News
-
-
-
PRESS RELEASE
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate. Study results confirm safety profile & effectiveness equal to standard care in reducing blood loss. Biotest aims to address global medical need with USD 800 million market potential -
-
-
PRESS RELEASE
EQS-Adhoc: Biotest AG: Increase of the EBIT guidance
-
-
-
-